Locations and Appointments
Please contact the doctor's office to verify that your insurance is accepted.
- Blue Access
- Blue Connection
- Mediblue (Senior)
- Medicare Advantage
- Community Plan
About Michal Bar-Natan, M.D.
I am a hematologist–oncologist specializing in the care of patients with acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. My goal is to provide the best possible care for these patients, and to discover novel and scientifically-based treatments that can improve outcomes for patients with these diseases.
I am committed to combining compassionate and personalized patient care with cutting-edge, patient-focused, and translational research. I strive to develop treatment plans designed to fit each patient’s individual needs, as well as the biology of their tumor.
As a physician/researcher at Weill Cornell Medicine and NewYork-Presbyterian, I have the privilege of working with a multidisciplinary group of experts who provide outstanding comprehensive clinical care for patients with myeloid malignancies and acute leukemia in addition to collaborating with laboratory-based research scientists to discover innovative therapeutic approaches. Additionally, together we design early phase clinical trials to evaluate these approaches and medications with the goal of improving the outcomes of patients with hematological malignancies.
Michal Bar-Natan, MD, is Interim Assistant Professor of Medicine and a member of the Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York City.
Dr. Bar-Natan graduated cum laude from the Sackler School of Medicine. She completed her Internal Medicine Residency at Sheba Medical Center and her Fellowship in Hematology and Medical Oncology at NYU Langone Health. In addition to her clinical fellowship training, Dr. Bar-Natan completed a research fellowship at Dana Farber Cancer Institute and Brigham and Women’s Hospital (Harvard Medical School) with a focus on the role that signal transducer and activator of transcription (STAT) proteins play in the development and treatment of myeloproliferative neoplasms (MPNs) and leukemias.
Prior to this position Dr. Bar-Natan served as Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai, an Attending Physician with the Center of Excellence for Blood Cancers and Myeloid Disorders, and as the leader of the Acute Lymphoblastic Leukemia program at the Mt. Sinai Tisch Cancer Institute.
Dr. Bar-Natan’s focus is on translational research in malignant hematology, particularly myeloid malignancies and acute lymphoblastic leukemia, and the development of investigator-initiated clinical trials for patients with these conditions. She leads early phase clinical trials implementing new therapeutic approaches, such as immunotherapies and combination therapies, and serves as the PI and co-investigator on many clinical trials for acute leukemias and myeloproliferative neoplasms.
B.Med.Sc.Sackler School of Medicine, Tel Aviv University (Israel)1999
M.D.Sackler School of Medicine, Tel Aviv University (Israel)1999
Assistant Attending HematologistNewYork-Presbyterian Hospital
Assistant Professor of Clinical Medicine (Interim)Weill Cornell Medical College, Cornell University
Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.